Event-Free Survival

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan